Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This study consists of four parts, Parts A, B, C, and D.
- Part A is a single dose pharmacokinetic (PK) study in pediatric participants with Sickle
Cell Disease ages 6 to 17 years.
- Part B is a multiple dose, safety, exploratory, efficacy, and PK study in adolescent
participants with Sickle Cell Disease ages 12 to 17 years.
- Part C is a multiple dose, safety, tolerability, and PK study, which includes the
assessment of hematological effects and the effect on TCD flow velocity of voxelotor in
pediatric participants with Sickle Cell Disease ages 4 to 17 years.
- Part D is a multiple dose, safety, tolerability, and PK study, which examines the
hematological effects of voxelotor in pediatric participants with Sickle Cell Disease
ages 6 months to < 4 years.
Phase
Phase 2
Funding Agency/Sponsor
Industry
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
- Male or female participants with homozygous hemoglobin SS (HbSS) or hemoglobin S beta0
thalassemia (HbS β0thal)
- Age:
- Part A - 6 to 17 years of age
- Part B - 12 to 17 years of age
- Part C - 4 to 17 years of age
- Part D - 6 months to <4 years of age
- Hydroxyurea (HU) therapy:
- Parts A, B, and C: A participant taking hydroxyurea (HU) may be enrolled if the
dose has been stable for at least 3 months with no anticipated need for dose
adjustment during the study and no sign of hematological toxicity.
- Part D: A participant taking HU may be enrolled if the dose has been stable for
at least 1 month. Titration to the maximum tolerated dose (MTD) is allowed during
the study.
- Hemoglobin (HB):
- Part A - No restriction
- Parts B, C, & D - Hb ≤ 10.5 g/dL
- For Part C only: Participants 12 to 17 years of age must have a TCD velocity of ≥ 140
cm/sec measured anytime during screening.
Exclusion Criteria:
- Any one of the following requiring medical attention within 14 days of signing the
Informed Consent Form (ICF):
- Vaso-occlusive crisis (VOC)
- Acute chest syndrome (ACS)
- Splenic sequestration crisis
- Dactylitis
- Requires chronic transfusion therapy
- History of stroke or meeting criteria for primary stroke prophylaxis (history of two
TCD measurements ≥ 200 cm/sec by non-imaging TCD or ≥185 cm/sec by TCDi).
- Transfusion within 30 days prior to signing the ICF
Exclusion Criteria for Part D Only:
- Body weight <5 kg for 1 month prior to the screening visit and at the screening visit.